因COVID-19不可逆肺损伤住院患者肺移植后并发症发生率更高,但1年生存率与限制性肺疾病住院移植患者相似
该研究比较了因COVID-19相关急性呼吸窘迫综合征(CARDS)与限制性肺疾病(RLD)住院接受肺移植患者的结局。2014至2021年间共纳入132例住院肺移植受者,其中CARDS组11例(8.3%),RLD组121例(91.7%)。倾向性匹配分析显示CARDS组移植后住院时间更长、ACR≥A2和DSA>2000 MFI发生率更高,但1年生存率与RLD组相当。
要点
- 住院肺移植受者中,CARDS组占8.3%(11/132),RLD组占91.7%(121/132)。
- CARDS组较RLD组更年轻,移植前住院时间更长,移植前机械通气、透析和ECMO桥接比例更高。
- 匹配分析显示CARDS组移植后住院时间更长,ACR≥A2和DSA>2000 MFI发生率更高,但1年生存率相当。
核心结论
- 即使经过仔细筛选,CARDS患者肺移植仍与显著并发症相关,但CARDS受者的1年生存率与匹配的住院RLD受者相当。
研究设计与样本
- 回顾性比较研究,纳入2014至2021年间住院的≥18岁CARDS或RLD肺移植受者,共132例符合标准,其中CARDS组11例(8.3%),RLD组121例(91.7%)。
- 对CARDS组每例患者采用logistic回归模型进行1:1匹配RLD组患者分析。
主要发现
- 764例肺移植受者中163例(21.3%)移植时住院,132例符合纳入标准。
- CARDS组较RLD组更年轻,移植前住院时间更长,移植前机械通气、透析和ECMO桥接比例更高。
- 倾向性匹配分析显示两组胸内粘连发生率、移植后机械通气时长、72小时PGD3和延迟关胸率相当。
- 与RLD组相比,CARDS组移植后住院时间显著更长,ACR≥A2和DSA>2000 MFI发生率更高,但1年生存率相当。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hospitalized lung transplant (LT) recipients (LTRs) have higher post-LT morbidity and mortality than those who are well enough to wait for transplant at home. Outcomes after LT for COVID-19-associated acute respiratory distress syndrome (CARDS) may be even worse; thus, we compared post-LT outcomes between hospitalized LTRs transplanted for CARDS and those transplanted for restrictive lung disease (RLD). METHODS: Between 2014 and 2021, hospitalized LTRs ≥18 years old with CARDS or RLD were included. Primary and secondary outcomes were 1-year post-LT survival and postoperative morbidity. For each patient in the CARDS group, an analysis of 1-to-1 matched patients from the RLD group was performed using logistic regression modeling. RESULTS: Of 764 LTRs, 163 (21.3%) were hospitalized at the time of LT; 132 met the inclusion criteria: 11 (8.3%) were transplanted for CARDS and 121 (91.7%) for RLD. LTRs with CARDS were younger with longer pre-LT hospitalization stays and higher rates of pretransplant mechanical ventilation, dialysis, and ECMO as a bridge to transplant. A propensity-matched analysis demonstrated comparable rates of intrathoracic adhesions, posttransplant duration of mechanical ventilation, PGD3 at 72 hours, and delayed chest closure. Compared to LTRs with RLD, those with CARDS had significantly longer posttransplant hospital stays and a higher prevalence of ACR ≥A2 and DSA >2000 MFI, but comparable 1-year survival rates. CONCLUSION: Even with careful selection, LT for patients with CARDS was associated with significant morbidity; however, 1-year survival of recipients with CARDS was comparable to that of matched hospitalized recipients with RLD.
引用
- Razia D, Olson MT, Grief K, et al. Hospitalized patients with irreversible lung injury from COVID-19 have higher morbidity but similar 1-year survival after lung transplant compared to hospitalized patients transplanted for restrictive lung disease. J Heart Lung Transplant. 2022. PMID: 36272894. doi:10.1016/j.healun.2022.09.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。